Capital and Coast District Health Board logo

ODYSSEY

Phone: Diane Middleditch on 04 9185726

Email: Diane.Middleditch@ccdhb.org.nz 

Trial website: https://clinicaltrials.gov/ct2/show/NCT01663402

Primary objective: To compare the effect of alirocumab with placebo on the occurrence of cardiovascular events (composite endpoint of coronary heart disease (CHD) death, non-fatal myocardial infarction (MI), fatal and non-fatal ischemic stroke, unstable angina requiring hospitalization) in patients who have experienced an acute coronary syndrome (ACS) event 4 to 52 weeks prior to randomization and are treated with evidence-based medical and dietary management of dyslipidemia.

 

Last updated 7 August 2017.